Information Provided By:
Fly News Breaks for May 19, 2017
INCY, MRK
May 19, 2017 | 08:50 EDT
BMO Capital analyst Alex Arfaei says that "the ASCO abstracts solidify Merck's (MRK) significant leadership in the important 1L-NSCLC market." The analyst says that Incyte's (INCY) Epacadostat appears to be "adding meaningful clinical benefit to Keytruda." He believes that the data "clearly indicates" that Keytruda monotherapy should be the standard of care in about 25% of 1L-NSCLC patients.
News For MRK;INCY From the Last 2 Days
MRK
Jun 21, 2017 | 09:36 EDT
Leap Therapeutics (LPTX) announced that it has entered into a clinical trial collaboration agreement with Merck (MRK), to investigate Leap's DKK1 antagonist, DKN-01, in combination with Merck's anti-PD-1 therapy, Keytruda, in patients with relapsed or refractory advanced esophagogastric cancers. The study is expected to begin enrolling patients in the second-half of 2017. The collaboration agreement is between Leap and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
MRK
Jun 20, 2017 | 11:41 EDT
FDA Commissioner Scott Gottlieb, in prepared remarks for his appearance before a Senate panel, states that the agency will soon announce a plan to facilitate the approval of drugs including so-called "tumor-agnostic" therapies that target cancer-linked DNA, reported Bloomberg. The FDA last month approved the first tumor-agnostic drug when it allowed for expanded use of Merck's (MRK) Keytruda, while trials of Loxo Oncology's (LOXO) tumor-agnostic drug have shown that it shrank a variety of tumors, the report noted. Reference Link
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.